GLPwatch
Papers (10389)
Page 172 of 174, ranked by citation count.
- Renal Outcomes of GLP-1 Receptor Agonists and Tirzepatide Across CKD Stages and Metabolic Phenotypes (Type 2 Diabetes and/or Overweight/Obesity): A Scoping Review.
- Liquid Chromatography Evaluation of a Novel Graphitic Carbon Stationary Phase Using Glucagon-Like Peptide‑1 Analogs.
- Comparison chart: GLP-1 and GIP/GLP-1 receptor agonists for type 2 diabetes.
- Noninsulin drugs for type 2 diabetes.
- Cardiometabolic risk effects of weight-loss medications: An updated network meta-analysis.
- Transforming a protease inhibitor into a peptide Guardian: BBI-armed hydrogel beads for Oral delivery of active peptides.
- A renal indication for semaglutide (Ozempic).
- Efficacy and safety of anti-prediabetic drugs in patients with prediabetes: a Bayesian network meta-analysis.
- Predictors of weight reduction effectiveness with liraglutide in diabetes mellitus type 2 patients: a retrospective cohort study.
- An Ionic Liquid-Based Enteric Formulation for Enhanced Oral Delivery of Semaglutide in Type 2 Diabetes Mellitus.
- Table: GLP-1 and GIP/GLP-1 receptor agonists for type 2 diabetes.
- Bile acid diarrhoea.
- In T2D inadequately controlled with metformin, orforglipron reduced HbA<sub>1c</sub> more than oral semaglutide at 52 wk.
- [GLP-1 receptor agonists : impact on diabetic kidney disease].
- Drugs for type 2 diabetes.
- Mapping Global Research on Adverse Effects of GLP-1 Receptor Agonists (2006-2025): A Scopus-Based Bibliometric and Thematic Analysis.
- [Role of exendin-4 in cardiovascular diseases].
- In adults with T2D and ASCVD, tirzepatide was noninferior to dulaglutide for a composite CV outcome at a median 4 y.
- In patients with type 2 diabetes and high CV risk, liraglutide reduced a composite CV outcome at a median 3.8 y.
- Exenatide challenge in oral glucose tolerance test is insufficient for predictions of glucose metabolism and insulin secretion after sleeve gastrectomy (SG) in obese patients with type 2 diabetes: a pilot study to establish a preoperative model to estimate β-cell function following augmented glucagon-like peptide-1 secretion after SG.
- Does evidence matter? Comparative effectiveness research and prescribing of Type 2 diabetes mellitus drugs.
- Established and emerging pharmacologic options and unmet needs in HFpEF and HFmrEF.
- Study on chitosan/carrageenan core-shell nanoparticles for oral co-administration of insulin/exenatide enhance insulin secretion in type 2 diabetes.
- The Role of Glucagon-like Peptide 1 Receptor Modulators for the Management of Dumping Syndrome in Patients Who have Undergone Metabolic and Bariatric Surgery: a Scoping Review.
- [GLP-1 agonist supports weight loss].
- The Role of Glucagon-Like Peptide-1 Receptor Agonists in Hair Loss: Clinical Evidence and Proposed Mechanisms.
- Searching for New Pharmacological Treatments of Alcohol Use Disorder (AUD): Focus on GLP-1 Receptor Agonists.
- Real-world Impact of 3 and 4.5 mg Doses of Dulaglutide on Weight and Hemoglobin A1c in Patients With Type 2 Diabetes Mellitus.
- The novel GLP-1/GIP dual receptor agonist DA5-CH is superior to tirzepatide and exendin-4 in the 6-OHDA Parkinson rat model.
- Single-cell RNA sequencing reveals beneficial mechanisms of Exendin-4 in autoimmune uveitis.
- Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912-1920.
- Patient With Tirzepatide-treated Type 2 Diabetes With Difficult Visualization During Esophagogastroduodenoscopy.
- Insulinoma Unmasked By Tirzepatide: A Rare Case of Postprandial Hypoglycemia In a Nondiabetic Patient.
- A Narrative Review on GLP-1 Receptor Agonists for Obesity in Older Women: Maximizing Weight Loss While Preserving Lean Mass.
- The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis: A Review.
- Pharmaceutical Approval Update.
- Dysesthesia associated with GLP-1 agonist therapies: data-mining analysis and literature review.
- Severe diabetic ketoacidosis associated with insulin dose reduction after tirzepatide initiation.
- Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Glucagon-Like Peptide-1 Receptor Agonists.
- The Impact of GLP-1 Receptor Agonists on Hair: Beneficial Effects or Adverse Outcomes?
- Exenatide Reduces Graft Injury in a Rat Transplantation Model Using Kidneys Donated after Cardiac Death.
- Effects of tirzepatide, a dual GIP and GLP-1 receptor agonist, on blood pressure, cardiac function, and sympathetic nervous system in stroke-prone spontaneously hypertensive rats.
- [Pharmacological and clinical profiles of a human GLP-1 analogue, liraglutide (Victoza(®))].
- Will oral semaglutide be used to reduce cardiovascular risk in subjects with type 2 diabetes instead of subcutaneous semaglutide?
- Six-month effects of liraglutide and dapagliflozin on lipid profile, cardiovascular risk, and NT-proBNP levels in patients with metabolic dysfunction-associated steatotic liver disease.
- Clinical Efficacy of a Flavo-Proxylane Topical Regimen Pre- and Post-ultrasound Procedure for Subjects Undergoing Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Therapy.
- Efficacy and Safety of Tirzepatide in Refractory Hypoglycemia Associated with Esophagojejunostomy.
- Diverticular Stricture and Hepatic Abscess Formation During Tirzepatide Therapy for Obesity.
- Redefining Cystic Fibrosis-Related Diabetes Management With Tirzepatide: A Case Report.
- Liraglutide ameliorates diabetic lung injury and muscle damage via modulation of TLR4/NF-κB and Atrogin-1/AMPK signaling pathways.
- Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists in Type 2 diabetes.
- [Glucagon-like peptide-1 receptor agonists].
- Effectiveness and safety of once-weekly semaglutide: findings from the SEMACOL-REAL retrospective multicentric observational study in Colombia.
- THE EFFECT OF EXENATIDE THERAPY IN PREVIOUSLY INSULIN-TREATED TYPE 2 DIABETIC PATIENTS.
- [Promising molecules for treatment of hyperglycemia in patients with type 2 diabetes].
- The use of GLP-1 receptor agonists and subsequent risk of nicotine-related events: a cross- sectional study.
- IDeglira vs insulin degludec for type 2 diabetes: a systematic review and meta-analysis.
- LEAN mass Preservation with Resistance Exercise and Protein during semaglutide and tirzepatide therapy (LEAN-PREP study): a protocol for a randomised controlled trial.
- Amylin Revisited: A 5-Year Perspective on Its Emerging Role in the Treatment of Diabesity.
- Muscle atrophy associated with glucagon-like Peptide-1 receptor agonists: A population-based observational study.